

Michael J Grayling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2720689/publications.pdf>

Version: 2024-02-01

39
papers

518
citations

1039880

9
h-index

713332

21
g-index

40
all docs

40
docs citations

40
times ranked

1089
citing authors

#	ARTICLE	IF	CITATIONS
1	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. <i>British Journal of Cancer</i> , 2022, 126, 204-210.	2.9	1
2	Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials. <i>Statistics in Medicine</i> , 2022, , .	0.8	5
3	Response adaptive intervention allocation in stepped-wedge cluster randomized trials. <i>Statistics in Medicine</i> , 2022, 41, 1081-1099.	0.8	2
4	A stochastically curtailed single-arm phase II trial design for binary outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 671-691.	0.4	2
5	Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. <i>BMC Cancer</i> , 2022, 22, 111.	1.1	3
6	Optimised point estimators for multi-stage single-arm phase II oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 817-831.	0.4	1
7	When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. <i>European Journal of Cancer</i> , 2022, 166, 270-278.	1.3	0
8	Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials. <i>BMC Medical Research Methodology</i> , 2022, 22, 111.	1.4	1
9	Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. <i>World Neurosurgery</i> , 2022, 161, 316-322.	0.7	4
10	Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables. <i>Communications in Statistics - Theory and Methods</i> , 2021, 50, 18-34.	0.6	1
11	A stochastically curtailed two-arm randomised phase II trial design for binary outcomes. <i>Pharmaceutical Statistics</i> , 2021, 20, 212-228.	0.7	2
12	Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. <i>Pharmaceutical Statistics</i> , 2021, 20, 990-1001.	0.7	2
13	A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials. <i>American Statistician</i> , 2021, 75, 424-432.	0.9	25
14	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. <i>BMC Rheumatology</i> , 2021, 5, 21.	0.6	8
15	Accounting for variation in the required sample size in the design of group-sequential trials. <i>Contemporary Clinical Trials</i> , 2021, 107, 106459.	0.8	2
16	Characterising the allergic profile of children with cystic fibrosis. <i>Immunity, Inflammation and Disease</i> , 2021, , .	1.3	3
17	Ambulance documentation of stroke symptoms during the UK COVID-19 "Stay at Home" message. <i>Emergency Medicine Journal</i> , 2021, 38, 83-84.	0.4	2
18	Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. <i>JCO Precision Oncology</i> , 2021, 5, 1813-1820.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. <i>BMC Rheumatology</i> , 2021, 5, 54.	0.6	0
20	Impact of the COVID-19 lockdown on hangings attended by emergency medical services. <i>Resuscitation</i> , 2020, 157, 89-90.	1.3	8
21	A review of available software for adaptive clinical trial design. <i>Clinical Trials</i> , 2020, 17, 323-331.	0.7	14
22	A web application for the design of multi-arm clinical trials. <i>BMC Cancer</i> , 2020, 20, 80.	1.1	12
23	Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 360-374.	0.6	2
24	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1255-1262.	3.0	35
25	Quality of stepped-wedge trial reporting can be reliably assessed using an updated CONSORT: crowd-sourcing systematic review. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 77-88.	2.4	9
26	Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study. <i>Trials</i> , 2019, 20, 665.	0.7	1
27	Admissible multiarm stepped-wedge cluster randomized trial designs. <i>Statistics in Medicine</i> , 2019, 38, 1103-1119.	0.8	6
28	Re-formulating Gehan's design as a flexible two-stage single-arm trial. <i>BMC Medical Research Methodology</i> , 2019, 19, 22.	1.4	0
29	Calculations Involving the Multivariate Normal and Multivariate t Distributions with and without Truncation. <i>The Stata Journal</i> , 2018, 18, 826-843.	0.9	0
30	Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables. <i>The Stata Journal</i> , 2018, 18, 416-431.	0.9	0
31	Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. <i>BMJ: British Medical Journal</i> , 2018, 363, k1614.	2.4	235
32	Group sequential crossover trial designs with strong control of the familywise error rate. <i>Sequential Analysis</i> , 2018, 37, 174-203.	0.2	2
33	Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials. <i>Biometrical Journal</i> , 2018, 60, 903-916.	0.6	10
34	An optimised multi-arm multi-stage clinical trial design for unknown variance. <i>Contemporary Clinical Trials</i> , 2018, 67, 116-120.	0.8	6
35	Blinded and unblinded sample size reestimation in crossover trials balanced for period. <i>Biometrical Journal</i> , 2018, 60, 917-933.	0.6	7
36	Group sequential designs for stepped-wedge cluster randomised trials. <i>Clinical Trials</i> , 2017, 14, 507-517.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features. <i>Trials</i> , 2017, 18, 33.	0.7	51
38	Do single-arm trials have a role in drug development plans incorporating randomised trials?. <i>Pharmaceutical Statistics</i> , 2016, 15, 143-151.	0.7	22
39	phaseR: An R Package for Phase Plane Analysis of Autonomous ODE Systems. <i>R Journal</i> , 2014, 6, 43.	0.7	18